Will Eli Lilly Do a Stock Split in 2024?

Core Viewpoint - Eli Lilly has not conducted a stock split in decades, with the last one occurring in 1997, and there is speculation about a potential split as its stock price approaches $1,000 [1][2][3] Group 1: Stock Performance and Market Position - Eli Lilly's stock has generated nearly 800% returns over the past five years, making it the most valuable healthcare stock globally, with a market cap around $850 billion [2] - The company is on track to potentially join the trillion-dollar club in the future [2] Group 2: Stock Split Considerations - A stock split could make shares more accessible to a broader range of investors, but it is not guaranteed that Eli Lilly will proceed with one [1][3] - Management decisions will ultimately determine if a stock split occurs, and there are no certainties regarding the timing of such an announcement [3] Group 3: Investment Potential - Eli Lilly is considered a strong investment opportunity due to its promising growth prospects, particularly from its weight loss and diabetes treatments, Zepbound and Mounjaro, which could generate significant revenue [4] - The company currently trades at a price-to-earnings multiple of nearly 140, indicating a high valuation, yet it is still viewed as a fantastic investment regardless of a potential stock split [4]